Diagnosing mild cognitive impairment (MCI) in clinical trials: A systematic review

BMJ Open

Volumn 3, Issue 2, 2013, Pages

  Christa Maree Stephan, Blossom ^a   Minett, Thais ^b   Pagett, Emma ^b   Siervo, Mario ^a   Brayne, Carol ^b   McKeith, Ian G ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; AGED; ALZHEIMER DISEASE; CLINICAL ASSESSMENT; COGNITION; DEMENTIA; DEMOGRAPHY; FRONTOTEMPORAL DEMENTIA; HUMAN; LEWY BODY; MEMORY DISORDER; META ANALYSIS; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REVIEW; STUDY DESIGN; SYSTEMATIC REVIEW;

EID: 84875043123     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001909     Document Type: Review

References (72)

1. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003;2:646-53. (Pubitemid 37361768)
2. Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011;76:280-6.
3. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. (Pubitemid 29120227)
4. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-92. (Pubitemid 33143977)
5. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
6. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72:1555-61.
7. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. Am J Alzheimers Dis Other Dementias 2005;20:295-302. (Pubitemid 41502371)
8. Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 2007;27:67-70. (Pubitemid 46105768)
9. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352:2379-88. (Pubitemid 40958434)
10. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by b vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010;5:1-10.
11. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-15. (Pubitemid 40720980)
12. Winblad B, Gauthier S, Scinto L, et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 2008;70:2024-35.
13. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1538-44.
14. Chen X, Magnotta VA, Duff K, et al. Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits. J Neuropsychiatry Clin Neurosci 2006;18:178-85.
15. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006;56:159-64. (Pubitemid 44374788)
16. Forlenza OV, Diniz BS, Radanovic M, et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry 2011;198:351-6.
17. Sherwin BB, Chertkow H, Schipper H, et al. A randomized controlled trial of estrogen treatment in men with mild cognitive impairment. Neurobiol Aging 2011;32:1808-17.
18. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
19. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol 2010;67:71-9.
20. Scherder EJ, Van Paasschen J, Deijen JB, et al. Physical activity and executive functions in the elderly with mild cognitive impairment. Aging Ment Health 2005;9:272-80. (Pubitemid 40780419)
21. Jean L, Simard M, Wiederkehr S, et al. Efficacy of a cognitive training programme for mild cognitive impairment: results of a randomised controlled study. Neuropsychol Rehabil 2010;20:377-405.
22. Rapp S, Brenes G, Marsh AP. Memory enhancement training for older adults with mild cognitive impairment: a preliminary study. Aging Mental Health 2002;6:5-11. (Pubitemid 34146143)
23. Troyer AK, Murphy KJ, Anderson ND, et al. Changing everyday memory behaviour in amnestic mild cognitive impairment: a randomised controlled trial. Neuropsychol Rehabil 2008;18:65-88. (Pubitemid 350223208)
24. Kinsella GJ, Mullaly E, Rand E, et al. Early intervention for mild cognitive impairment: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2009;80:730-6.
25. Buschert VC, Friese U, Teipel SJ, et al. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study. J Alzheimers Dis 2011;25:679-94.
26. Rozzini L, Costardi D, Chilovi V, et al. Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatric Psychiatry 2007;22:356-60. (Pubitemid 46680847)
27. Van Uffelen JGZ, Hopman-Rock M, Chin A, et al Protocol for Project FACT: a randomised controlled trial on the effect of a walking program and vitamin B supplementation on the rate of cognitive decline and psychosocial wellbeing in older adults with mild cognitive impairment [ISRCTN19227688]. BMC Geriatrics 2005;5. doi:10.1186/1471-2318-1185-1118
28. Roth M, Tym E, Mountjoy CQ, et al. CAMDEX: the cambridge examination for mental disorders of the elderly. Cambridge: Cambridge University Press, 1988.
29. Gilewski MJ, Zelinski EM. Memory Functioning Questionnaire (MFQ). Psychopharmacol Bull 1988;24:665-70. (Pubitemid 19054373)
30. Strawbridge WJ, Shema SJ, Balfour JL, et al. Antecedents of frailty over three decades in an older cohort. J Gerontol Series B, Psychol Sci Soc Sci 1998;53:S9-16. (Pubitemid 28087528)
31. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
32. Jurica PJ, Leitten CL, Mattis S. Dementia rating scale-2: professional manual. Lutz: Psychological Assessment Resources, 2001.
33. Mattis S. Dementia rating scale: orofessional manual. Odessa, FL: Psychological Assessment Resources, 1988.
34. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. Neuropsychiatry Neuropsychol Behav Neurol 1988;1:111-17. (Pubitemid 20164001)
35. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72. (Pubitemid 12124384)
36. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-64.
37. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11:S22-32.
38. Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20:310-19. (Pubitemid 28539551)
39. Hebert R, Carrier R, Bilodeau A. The Functional Autonomy Measurement System (SMAF): description and validation of an instrument for the measurement of handicaps. Age Ageing 1988;17:293-302. (Pubitemid 18263777)
40. Morris JC, Mohs RC, Rogers H, et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-52. (Pubitemid 19054370)
41. Kempen GI, Miedema I, Ormel J, et al. The assessment of disability with the Groningen activity restriction scale. Conceptual framework and psychometric properties. Soc Sci Med 1996;43:1601-10. (Pubitemid 26397735)
42. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-86.
43. Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist 1970;10:20-30.
44. Wedderburn C, Wear H, Brown J, et al. The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry 2008;79:500-3. (Pubitemid 351571865)
45. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Third Edition, revised) (DSM-III-R). Washington, DC: APA, 1987.
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (Fourth Edition) (Text Revision: DMS-IV-TR). Arlington, VA: American Psychiatric Publishing Inc, 2000.
47. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44. (Pubitemid 14076461)
48. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60. (Pubitemid 23060253)
49. Reisberg B, Ferris SH, de Leon MJ, et al. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-9. (Pubitemid 12051593)
50. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatric Psychiatry 2012;26:592-600.
51. Jorm AF. The Informant Questionnaire on cognitive decline in the elderly (IQCODE): a review. Int Psychogeriatr 2004;16:275-93. (Pubitemid 39441493)
52. EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
53. Ebly EM, Hogan DB, Parhad IM. Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol 1995;52:612-19.
54. Duara R, Loewenstein DA, Greig MT, et al. Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatric Psychiatry 2011;19:951-60.
55. Stephan BC, Matthews FE, Khaw KT, et al. Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimer's Res Ther 2009;1:4.
56. Stephan BC, Matthews FE, McKeith IG, et al. Early cognitive change in the general population: how do different definitions work? J Am Geriatr Soc 2007;55:1534-40. (Pubitemid 47508512)
57. Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 2008;56:1424-33.
58. Erkinjuntti T, Ostbye T, Steenhuis R, et al. The effect of different diagnostic criteria on the prevalence of dementia. N Engl J Med 1997;337:1667-74. (Pubitemid 27510105)
59. Wancata J, Borjesson-Hanson A, Ostling S, et al. Diagnostic criteria influence dementia prevalence. Am J Geriatric Psychiatry 2007;15:1034-45.
60. Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: a systematic review. Int J Geriatr Psychiatry 2009;24:902-15.
61. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia - meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 2009;119:252-65.
62. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15-21.
63. Panza F, Capurso C, D'Introno A, et al. Heterogeneity of mild cognitive impairment and other predementia syndromes in progression to dementia. Neurobiol Aging 2007;28:1631-2. (Pubitemid 47243690)
64. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201-9.
65. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010;9:1118-27.
66. Whitehair DC, Sherzai A, Emond J, et al. Influence of apolipoprotein e (epsilon)4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's Dementia 2010;6:412-19.
67. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
68. Gauthier S, Reisberg B, Zaudig M, et al. Mild cognitive impairment. Lancet 2006;367:1262-70.
69. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
70. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-6. (Pubitemid 39222993)
71. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
72. Matthews FE, Stephan BC, Bond J, et al. Operationalization of mild cognitive impairment: a graphical approach. PLoS Med 2007;4:1615-19. (Pubitemid 350035445)